Integril 2

• Acute Coronary Syndrome (Unstable Angina/NSTEMI): Indicated for patients to be managed medically and those undergoing PCI.
• Percutaneous Coronary Intervention (PCI): Indicated for patients undergoing PCI, including those undergoing intracoronary stenting.

Eptifibatide is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction), including patients who are to be managed medically and those undergoing PCI. For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting.

Adult Dose (Normal Renal Function):

• Acute Coronary Syndrome: 180 mcg/kg IV bolus, THEN 2 mcg/kg/min IV infusion for up to 72 hr.
• PCI: 180 mcg/kg IV bolus (before procedure), THEN 2 mcg/kg/min IV infusion; second 180 mcg/kg IV bolus 10 min after first.

Renal Dose (CrCl <50 mL/min):

• ACS: 180 mcg/kg IV bolus, THEN 1 mcg/kg/min IV infusion.
• PCI: 180 mcg/kg IV bolus, THEN 1 mcg/kg/min IV infusion; second 180 mcg/kg IV bolus 10 min after first.

Common Side Effects:

• Bleeding (mostly at femoral artery access site)
• Decreased blood pressure
• Intracranial hemorrhage and stroke (rare)
• Thrombocytopenia
• Allergic reactions

Use in Pregnancy: Category B. Animal studies revealed no evidence of harm to the fetus. However, no adequate and well-controlled studies in pregnant women. Should be used only if clearly needed.

Precautions:

• Eptifibatide is intended for use in hospitalized patients.
• It is usually given by your nurse or doctor as an infusion (drip) into a vein.
• It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails or using sharp objects.
• Notify your doctor if you see blood in your vomit, urine or stool.
• In patients undergoing PCI, there is an increase in bleeding at the site of arterial sheath placement.
• Caution in patients with platelet count <100,000/mm³.
• Avoid use with other GP IIb-IIIa inhibitors.

Overdose: Limited experience with overdosage. In animal studies, symptoms included: loss of righting reflex, dyspnea, ptosis, decreased muscle tone, and petechial hemorrhages. Eptifibatide is not extensively bound to plasma proteins and may be cleared by dialysis.

Storage: Vials should be stored refrigerated at 2-8°C. Vials may be transferred to room temperature for up to 2 months. Protect from light until administration.